Coerente Capital Management Sells 14,069 Shares of CVS Health Corporation $CVS

Coerente Capital Management lowered its position in shares of CVS Health Corporation (NYSE:CVS) by 18.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,599 shares of the pharmacy operator’s stock after selling 14,069 shares during the quarter. CVS Health accounts for about 0.8% of Coerente Capital Management’s investment portfolio, making the stock its 24th largest position. Coerente Capital Management’s holdings in CVS Health were worth $4,352,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CVS. Norges Bank bought a new position in CVS Health in the 4th quarter worth $1,666,265,000. Wellington Management Group LLP lifted its position in shares of CVS Health by 193.2% in the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after acquiring an additional 12,233,675 shares in the last quarter. Amundi boosted its stake in shares of CVS Health by 95.3% in the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after acquiring an additional 3,637,943 shares during the period. Capital Research Global Investors boosted its stake in shares of CVS Health by 24.5% in the third quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after acquiring an additional 2,253,531 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of CVS Health by 70.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after purchasing an additional 2,188,307 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the sale, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,441,551 shares of company stock worth $323,703,977 in the last 90 days. 0.85% of the stock is currently owned by company insiders.

CVS Health Stock Performance

NYSE CVS opened at $101.68 on Wednesday. The stock has a market capitalization of $129.74 billion, a PE ratio of 44.79, a P/E/G ratio of 0.99 and a beta of 0.62. The business has a 50 day simple moving average of $90.21 and a two-hundred day simple moving average of $81.86. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $103.12.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts predict that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Pharmacy is expanding GLP-1 support across more than 9,000 locations and MinuteClinic, including lower costs, access help, and therapy support, which could boost patient engagement and prescription volume. CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Positive Sentiment: CVS is adding a new $49 virtual MinuteClinic visit and broader weight-management support, reinforcing growth in its consumer health services. CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Positive Sentiment: Traders bought an unusually large number of CVS call options, suggesting bullish sentiment in the stock.
• Positive Sentiment: Third-party research pieces highlighted CVS as a top-ranked value and long-term momentum stock, which may be supporting investor confidence. CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
• Positive Sentiment: CVS also received upbeat coverage for expanding its GLP-1 support, helping explain the stock’s recent outperformance. CVS Health Expands GLP-1 Support for Patients
• Neutral Sentiment: CVS highlighted community and public-health initiatives, including HIV awareness and a grand opening event in New Jersey, but these are unlikely to move the stock materially. CVS Health: Thank You! Mews at St. Mary Grand Opening – Williamstown, NJ
• Neutral Sentiment: Articles noting CVS was “under the microscope” after a healthcare report could keep some regulatory scrutiny in focus, but the details provided do not indicate an immediate financial hit. CVS Health (CVS) Under the Microscope After Recent Healthcare Report

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of research analyst reports. Wolfe Research lowered their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Deutsche Bank Aktiengesellschaft increased their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Argus lifted their price objective on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Sanford C. Bernstein upped their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, TD Cowen raised their target price on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus price target of $101.28.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.